Professor Daniel Peckham
- Position: Professor of Respiratory Medicine (Clinical)
- Areas of expertise: Respiratory Medicine; Cystic Fibrosis; Bronchiectasis; Primary Ciliary Dyskinesia; Lung Infection; Inflammation; Allergy; Inflammasome; Informatics; Ion Transport; Microbiome; cancer
- Email: D.G.Peckham@leeds.ac.uk
- Phone: +44(0)113 206 5282
- Location: 8.19 Clinical Sciences Building, St James’s University Hospital
- Website: Chest Medicine | Cystic Fibrosis Medicine | Twitter | LinkedIn | Googlescholar | Researchgate | ORCID
Profile
I created and head up a dedicated Research unit focusing on various aspects of Cystic Fibrosis, Bronchiectasis, Primary Ciliary Dyskinesia, Respiratory Medicine and Medical Informatics. I graduated from Westminster and Charing Cross Medical School (University of London) in 1987. In 1992, I was appointed adult Cystic Fibrosis Research Fellow at City Hospital in Nottingham where I completed my doctoral thesis “Airway Epithelial Sodium Potassium ATPase activity and Cystic Fibrosis”. Working in Nottingham triggered my passion for research and cystic fibrosis.
After working as a senior registrar in Oxford, I moved to Leeds in 1998 as a full-time NHS consultant with a specialist interest in Cystic Fibrosis and Pulmonary infections. I was clinical lead for Respiratory Medicine for nearly a decade, a role I thoroughly enjoyed for nearly a decade and which enabled me to support, in collaboration with my colleagues, the expansion and modernisation of specialist services and clinical research.
In 2016, I was appointed as the first Professor of Respiratory Medicine (clinical) at the University of Leeds. As lead for cystic fibrosis, bronchiectais and primary ciliary dyskinesia, I continue to combine clinical practice with scientific research.
Professional activities
UK CF Trust CTAP (2018-)
Board Member of the European Cystic Fibrosis Society (2015-2022)
Founding Director of Education for the European Cystic Fibrosis Society (2018-2022)
Deputy Director of Education for the European Cystic Fibrosis Society (2022-)
Director of the Leeds Adult Cystic Fibrosis Service (2006-)
Leeds for Adult PCD services (2019-)
Lead for Adult bronchiectasis services (1998-)
Member of the European Clinical Trial Network (2012)
Trustee of Ali's Gift Charity (2016-)
Responsibilities
- Director of the Regional Adult Cystic Fibrosis and bronchiectasis Unit
- Symposium Lead, Respiratory Clinical Symposia, Body Systems, MB ChB years 1
- Deputy Director of the Leeds Institute of Medical Research
Research interests
Specialist interest include medical informatics. Active research focusing on various aspects of CF, bronchiectasis and Primary Ciliary Dyskinesia. Work focusing on inflammation (NLRP3) , infection, gut microbiome, drug allergy, adherence, data flow, electronic patient records and clinical trials.
- Cystic Fibrosis
- Health Informatics
- Bronchiectasis
- Primary ciliary dyskinesia
- Respiratory Medicine
- Drug Allergy
- Inflammation
- NLRP3 inflammasome
- Arthopathy
- Ion transport
- Gut microbiome
- Infection
- Airborne transmission
- Psychology
- Adherence
- Clinical trials (CTAP) (ECTN)
Qualifications
- MBBS
- DM
- FRCP
Professional memberships
- European Cystic Fibrosis Society
- European Respiratory Society
- British Thoracic Society
- Royal College of Physicians
- Yorkshire Thoracic Society
Student education
MB ChB years 1 – Strand Lead for the Respiratory Strand / Respiratory symposia
Research groups and institutes
- Leeds Institute of Medical Research at St James's
Current postgraduate researchers
<h4>Postgraduate research opportunities</h4> <p>We welcome enquiries from motivated and qualified applicants from all around the world who are interested in PhD study. Our <a href="https://phd.leeds.ac.uk">research opportunities</a> allow you to search for projects and scholarships.</p>Projects
-
<li><a href="//phd.leeds.ac.uk/project/1779-limr-cancer:-investigation-of-accentuated-mitochondrial-ros-and-nlrp3-inflammasome-activation-in-cystic-fibrosis-and-colorectal-carcinoma.">LIMR Cancer: Investigation of accentuated mitochondrial ROS and NLRP3 inflammasome activation in cystic fibrosis and colorectal carcinoma.</a></li>